tbuckley/cabot-search huggingface dataset:
Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions
Authors: Rishi J. Desai, Krista F. Huybrechts, Brian T. Bateman, Sonia Hernandez‐Diaz, Helen Mogun, Chandrasekar Gopalakrishnan, Elisabetta Patorno, Seoyoung C. Kim
Journal: Arthritis & Rheumatology (2015)

To describe patterns and secular trends in the use of immunomodulatory agents in pregnant women with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS).We identified a cohort of women with SLE, RA, PsA, or AS enrolled in public (Medicaid, 2001-2010) or private (Optum Clinformatics, 2004-2012) health insurance, and we included women filling prescriptions for immunomodulatory agents (including steroids, nonbiologic disease-modifying agents, and biologic agents) in the 3-month period immediately prior to their pregnancies. The proportion of women continuing or discontinuing individual agents during pregnancy was reported. Annual prescription fill rates, estimated after accounting for patient characteristics and random variability from year to year in mixed-effects regression models, were used to conduct time trends analysis.We included 2,645 women being treated with immunomodulatory agents prior to pregnancy. More women with PsA or AS stopped filling prescriptions for immunomodulatory agents during pregnancy (61%) than women with SLE (26%) or women with RA (34.5%). From the first to the third trimester, the proportions of women filling prescriptions for immunomodulatory agents decreased across all indications. Overall, steroids and hydroxychloroquine were the most frequently used agents in pregnancy (48.4% and 27.1%, respectively). The rates (reported per 100 deliveries in our cohort) for steroid prescription fills during pregnancy decreased significantly from 54.4 in 2001 to 42.4 in 2012, while rates for biologic agents increased from 5.1 in 2001 to 16.6 in 2012 (P < 0.001 for both trends).Steroids and hydroxychloroquine remain the most widely prescribed treatment options in pregnancy, but the use of biologic agents is becoming increasingly common.
Diagnostic Radiology for Cancer
Authors: J J Stein
Journal: CA A Cancer Journal for Clinicians (1974)

Thediagnosticradiologistoccupies a uniquepositionasconsultant to all physicians in the management of patients wit/i cancer. Dr. Stein:That's true.He helps not only establish the diagnosis of cancer but also aids in accurately locating and staging the disease.For in stance, techniques like specimen radiography, fluoroscopy and lymphangiography identify sites for biopsy.Diagnostic radiology also provides data for judging response to therapy, establishing baseline studies and following the patient's progress.
Tobacco-Smoking Habits in an American City
Authors: Clarence A. Mills, M. D., Marjorie Mills Porter, M. D.
Journal: JNCI Journal of the National Cancer Institute (1953)

Tobacco-Smoking Habits in an American City Get access Clarence A. Mills, M. D., Clarence A. Mills, M. D. Search for other works by this author on: Oxford Academic PubMed Google Scholar Marjorie Mills Porter, M. D. Marjorie Mills Porter, M. D. Laboratory for Experimental Medicine, University of Cincinnati, Cincinnati, Ohio Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 13, Issue 5, April 1953, Pages 1283–1297, https://doi.org/10.1093/jnci/13.5.1283 Published: 01 April 1953 Article history Received: 28 November 1952 Published: 01 April 1953
Immunologic Tolerance to Antigens Associated With Murine Leukemia Viruses: T-Cell Unresponsiveness 2
Authors: L. Chieco-Bianchi, F. Sendo, T. Aoki, O. L. Barrera
Journal: JNCI Journal of the National Cancer Institute (1974)

To test whether the cell-mediated immune response of murine leukemia virus (MuLV) carrier mice is specifically depressed, adult C57BL/6 mice, neonatally infected with Moloney (M)-MuLV, were immunized with M-MuLV-induced leukemia BALB/c cells (YC8, LSTRA). Their spleen lymphocytes were assayed at various intervals after immunization with syngeneic M-MuLV-induced leukemia cells (MBL-2) by use of 51Cr-releasing lymphocyte-mediated cytotoxicity (LMC). In contrast with similarly immunized control mice, spleen lymphocytes from M-MuLV neonatally infected mice showed no reactivity, but these cells were fully reactive when tested against radiation-induced leukemia BALB/c cells (BALB.RL♂1). No blocking activity to M-MuLV-associated antigens was found with different sera from M-MuLV neonatally infected and immunized mice. These results, together with the finding that the active lymphocytes in LMC were sensitive to pretreatment with anti-θ serum, suggest that a state of thymus-derived (T)-cell unresponsiveness occurs in neonatally infected mice. Though the neutralizing antibody to M-MuLV was not found in M-MuLV neonatally infected C57BL/6 mice, we demonstrated in another study the presence of specific humoral antibody to M-MuLV reverse transcriptase in the kidney eluate of similarly treated C57BL/6 mice. Therefore, partial tolerance to M-MuLV-associated antigens occurred in this system.
Why are Mexican data important?
Authors: D Coulombier, J Giesecke
Journal: Eurosurveillance (2009)

This issue of Eurosurveillance contains an article by a French team on the transmission of the new influenza A(H1N1) in Mexico, which uses published figures from the outbreak to estimate important parameters for transmission, among them the reproduction rate, R [1]. Such studies may have important implications for public health action in Europe.
The Value of Cosaldon in Cerebral Arteriosclerosis
Authors: I L FELSTEIN
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Microscopic (collagenous) colitis in a patient with a heart transplant
Authors: Tobias Rehlen, Felix Lasitschka, Regina Pribe-Wolferts, Wolfgang Stremmel, Hugo Katus, Andreas Dösch, Christoph Eisenbach
Journal: Endoscopy (2015)

A 62-year old female patient presented with symptoms of watery diarrhea, abdominal discomfort, and weight loss persisting for several weeks. The patient had undergone a heart transplant procedure 10 years earlier because of ischemic cardiomyopathy. Immunosuppression consisted of cyclosporin A and mycophenolate mofetil (CellCept; Genentech, South San Francisco, California, USA). Steroids had been stopped 3 months before.
The treatment of recurrent corneal erosion
Authors: M Potocký
Journal: JAMA (1987)

The author presents an account on 27 patients with relapsing corneal erosion 6 to 60 months after phototherapeutic keratectomy. The results of this treatment confirm unequivocally that the method is safe, highly effective and relieves the patient rapidly and for a long period (possibly permanently) of complaints. A disadvantage is the high cost of the equipment.
MB-06TREATMENT RESULTS OF MEDULLOBLASTOMA IN CHILDREN OLDER THAN 3 YEARS OF AGE ACCORDING TO MOLECULAR SUBGROUP-SPECIFIC RISK STRATIFICATION
Authors: Andrey Levashov, Anna Stroganova, Marina Rizhova, Dmitry Khochenkov, Stepan Babelyan, Natalya Subbotina, Vidmante Daylidite, Alexandr Popa, George Mentkevich, Igor Dolgopolov
Journal: Neuro-Oncology (2016)
Tropical Endomyocardial Fibrosis
Authors: Antonio Grimaldi, Ana Olga Mocumbi, Juergen Freers, Matthias Lachaud, Mariana Mirabel, Beatriz Ferreira, Kumar Narayanan, David S. Celermajer, Daniel Sidi, Xavier Jouven, Eloi Marijon
Journal: Circulation (2016)

Tropical endomyocardial fibrosis (EMF) is a neglected disease of poverty that afflicts rural populations in tropical low-income countries, with some certain high-prevalence areas. Tropical EMF is characterized by the deposition of fibrous tissue in the endomyocardium, leading to restrictive physiology. Since the first descriptions in Uganda in 1948, high-frequency areas for EMF have included Africa, Asia, and South America. Although there is no clear consensus on a unified hypothesis, it seems likely that dietary, environmental, and infectious factors may combine in a susceptible individual to give rise to an inflammatory process leading to endomyocardial damage and scar formation. The natural history of EMF includes an active phase with recurrent flare-ups of inflammation evolving to a chronic phase leading to restrictive heart failure. In the chronic phase, biventricular involvement is the most common presentation, followed by isolated right-sided heart disease. Marked ascites out of proportion to peripheral edema usually develops as a typical feature of EMF. EMF carries a very poor prognosis. In addition to medical management of heart failure, early open heart surgery (endocardectomy and valve repair/replacement) appears to improve outcomes to some extent; however, surgery is technically challenging and not available in most endemic areas. Increased awareness among health workers and policy makers is the need of the hour for the unhindered development of efficient preventive and therapeutic strategies.
The impending medical oncologist glut.
Authors: M B Van Scoy-Mosher
Journal: Journal of Clinical Oncology (1984)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1984.2.12.1425 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 6512586 The impending medical oncologist glut. M B Van Scoy-MosherxM B Van Scoy-MosherSearch for articles by this author https://doi.org/10.1200/JCO.1984.2.12.1425 PDF "The impending medical oncologist glut.." Journal of Clinical Oncology, 2(12), p. 1425© 1984 by American Society of Clinical Oncology
NS-22ENDOCRINE SEQUELAE FOLLOWING SURGERY FOR HYPOTHALAMIC HAMARTOMAS WITH INTRACTABLE EPILEPSY
Authors: Aliki Bogiatzopoulou, Arundoss Gangadharan, Mohammed Didi, Barry Pizer, Lisa Howell, James Hayden, Conor Mallucci, Benedetta Pettorini, Sasha Burn, Joanne Blair
Journal: Neuro-Oncology (2016)
LG-16RADIOGRAPHIC AND OPHTHALMOLOGIC CHARACTERISTICS OF OPTIC PATHWAY GLIOMA IN CHILDREN WITH NEUROFIBROMATOSIS 1
Authors: Elizabeth Unterbrink, Benita Tamrazi, Mark Borchert, Ashley Margol, Linda Randolph, Tena Rosser, Girish Dhall, Nathan Robison
Journal: Neuro-Oncology (2016)

LG-16. RADIOGRAPHIC AND OPHTHALMOLOGIC CHARACTERISTICS OF OPTIC PATHWAY GLIOMA IN CHILDREN WITH NEUROFIBROMATOSIS 1 Elizabeth Unterbrink1, Benita Tamrazi1,2, Mark Borchert1,2, Ashley Margol1,2, Linda Randolph1,2, Tena Rosser1,2, Girish Dhall1,2, and Nathan Robison1,2; Children’s Hospital Los Angeles, Los Angeles, CA, USA; University of Southern California Keck School of Medicine, Los Angeles, CA, USA OBJECTIVE: To describe the natural history of optic pathway glioma (OPG) in children with neurofibromatosis 1 (NF1). METHODS: The Children’s Hospital Los Angeles (CHLA) institutional review board approved this retrospective study. Using a clinical database, we identified children with NF1 and OPG followed at CHLAwith at least 1 MRI obtained at ,12 years of age from 6/1/1997-5/31/2014. Demographic, treatment, and visual field/ acuity data were extracted. MRIs were reviewed by a neuroradiologist. RESULTS: Of 63 children with NF1 and OPG, 50 had available imaging and were included. Mean age at initial MRI was 4.8 years; mean follow-up was 6.8 years. OPG was apparent on brain MRI in 4/7 children at ,2 years (57%; 95% confidence interval[95%CI] 20-94); 19/23 by 4 years (83%; 95%CI 67-98); 29/31 by 6 years (94%; 95%CI 85-100); and 50/50 by 12 years. Among 13 children (26%) who subsequently received tumor-directed treatment, OPG was MRI-apparent in 5/6 children by 4 years (83%; 95%CI 54-100), 8/9 by 6 years (89%; 95%CI 68-100) and 13/13 by 8 years. Among children with detailed visual outcome data, visual impairment was seen in 6/20 at , 4 years (30%; 95%CI 10-50); and 26/45 by 12 years (58%; 95%CI 43-72). A subset had normalization of vision, with persistent visual abnormalities in only 14/41 children on follow-up (34%; 95%CI 20-49). DISCUSSION: A minority of children without MRI-apparent OPG at initial evaluation eventually developed symptomatic disease. The high incidence of early-onset visual abnormalities highlights the importance of early NF1 diagnosis and ophthalmologic screening. Neuro-Oncology 18:iii78–iii96, 2016. doi:10.1093/neuonc/now075.16 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
The Quality of Survival (QoS): A concept framework to assist communication and decision making about cancer care.
Authors: Lesley Fallowfield, Eric Nadler, Maire Greaney, Adam Gater, Milayna Subar, Lucinda Strycker Orsini, Gary H. Lyman
Journal: Journal of Clinical Oncology (2016)

78 Background: The past decade has seen the development of transitional, novel cancer therapies that lengthen survival, yet data regarding the quality of that survival are limited or unavailable. Improving patient (pt)/healthcare professional (HCP) communication about issues such as QoS might enhance engagement and inform decision-making about future care. For example, the PROACT study (ECC 2015, abs.1715) has shown how little attention is given to family caregiver impact. Our objective is to develop an inclusive framework that will go beyond existing pt-reported outcomes and quality of life (QoL) constructs, and which HCPs may use to communicate with pts. Methods: An electronic database search to investigate the QoS landscape in cancer was conducted and results were articulated into a visual concept map. Subsequently, 20 US pts with metastatic NSCLC were interviewed about their cancer experiences (a similar melanoma pt survey is ongoing) and this input was integrated into the concept map. Areas explored include: symptoms, disease/treatment communication and education, pt expectations about treatment goals and involvement in decision-making, and impacts of all these on pts, families, and friends. Results: In their interviews, pts reported a host of impacts: physical, psychological/emotional, social/relationship, work, and financial. A QoS concept framework was developed to capture the holistic pt experience throughout the continuum of cancer care (during and post treatment) and consisted of 4 interconnected domains: QoL, survival, side effects and economic impact. The severity and persistence of some of the impacts ultimately affect survival, while others affect the ability to preserve or return to normality. Conclusions: While pt experiences are usually discussed and monitored by HCPs, issues identified as most important to pts and families and their variability over time, are rarely assessed formally during survival. These findings support the development of a pt-centric concept map that defines QoS, provides a comprehensive framework for improving communication between pts and their care teams about long-term QoS in cancer, and potentially enables better treatment decisions.
Abstract 126: PI3 kinase plays important role in c-Kit/V560D mediated oncogenic signaling
Authors: Jianmin Sun
Journal: Cancer Research (2015)

Abstract Oncogenic mutations of c-Kit are often identified in mastocytosis, gastrointestinal stromal tumors (GISTs) and acute myeloid leukemia (AML). The activation mechanism of the most often occurring mutation, D816V in exon 17 of c-Kit, has been well studied while other mutations remain fairly uncharacterized in this respect. In this study, we show that the constitutive activity of the exon 11 mutant V560D is weaker than the D816V mutant except that the phosphorylation of the Src family kinase binding site, Tyr568, is similar in both c-Kit mutants. The ligand for c-Kit, stem cell factor (SCF), induced phosphorylation of downstream signaling proteins, such as Akt and Erk, in c-Kit/V560D expressing cells was stronger than that in c-Kit/D816V expressing cells. Although cells expressing c-Kit/V560D showed increased ligand-independent proliferation and survival compared to wild-type c-Kit expressing cells, these biological effects were less than c-Kit/D816V expressing cells. In contrast to cells expressing wild-type c-Kit, cells expressing c-Kit/V560D are independent of Src family kinases for downstream signaling. However, this independence of Src family kinases is not due to a Src-like kinase activity of the mutant receptor that c-Kit-D816V holds. Blockage of the association of PI3 kinase with c-Kit/V560D by point mutation, but not inhibition of PI3-kinase with pharmacological inhibitors, totally blocked ligand-independent activation of the receptor, suggesting a key role of the non-lipid kinase activity of PI3 kinase in c-Kit/V560D mediated oncogenic signal transduction. Thus, PI3 kinase is an attractive treatment target in c-Kit mutations induced malignancies independent of its lipid kinase activity. Citation Format: Jianmin Sun. PI3 kinase plays important role in c-Kit/V560D mediated oncogenic signaling. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 126. doi:10.1158/1538-7445.AM2015-126
Genome-Wide Identification of Regulatory Sequences Undergoing Accelerated Evolution in the Human Genome
Authors: Xinran Dong, Xiao Wang, Feng Zhang, Weidong Tian
Journal: Molecular Biology and Evolution (2016)

Accelerated evolution of regulatory sequence can alter the expression pattern of target genes, and cause phenotypic changes. In this study, we used DNase I hypersensitive sites (DHSs) to annotate putative regulatory sequences in the human genome, and conducted a genome-wide analysis of the effects of accelerated evolution on regulatory sequences. Working under the assumption that local ancient repeat elements of DHSs are under neutral evolution, we discovered that ∼0.44% of DHSs are under accelerated evolution (ace-DHSs). We found that ace-DHSs tend to be more active than background DHSs, and are strongly associated with epigenetic marks of active transcription. The target genes of ace-DHSs are significantly enriched in neuron-related functions, and their expression levels are positively selected in the human brain. Thus, these lines of evidences strongly suggest that accelerated evolution on regulatory sequences plays important role in the evolution of human-specific phenotypes.
Combination Imatinib with Interferon-α For Philadelphia Positive Acute Lymphocytic Leukemia: A Mutiple Centers Study In China
Authors: Pu Kuang, Yu Wu, Bing Xiang, Hongbing Ma, Hong Chang, Ting Niu, Xu Cui, Chuan He, Jianjun Li, Jie Ji, Jie Huang, Tian Dong, Qing Shenglan, Huaxin Wu, Xiaogong Liang, Haiying Guo, Chunnong Wu, Ting Liu
Journal: Blood (2013)
Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion/Differentiation and Preclinical Proof of Concept
Authors: Afonso R. Almeida, Daniel V. Correia, Ana Fernandes-Platzgummer, Cláudia L. da Silva, Maria Gomes da Silva, Diogo Remechido Anjos, Bruno Silva-Santos
Journal: Clinical Cancer Research (2016)

The Vδ1+ subset of γδ T lymphocytes is a promising candidate for cancer immunotherapy, but the lack of suitable expansion/differentiation methods has precluded therapeutic application. We set out to develop and test (preclinically) a Vδ1+ T-cell-based protocol that is good manufacturing practice compatible and devoid of feeder cells for prompt clinical translation.We tested multiple combinations of clinical-grade agonist antibodies and cytokines for their capacity to expand and differentiate (more than 2-3 weeks) Vδ1+ T cells from the peripheral blood of healthy donors and patients with chronic lymphocytic leukemia (CLL). We characterized the phenotype and functional potential of the final cellular product, termed Delta One T (DOT) cells, in vitro and in vivo (xenograft models of CLL).We describe a very robust two-step protocol for the selective expansion (up to 2,000-fold in large clinical-grade cell culture bags) and differentiation of cytotoxic Vδ1+ (DOT) cells. These expressed the natural cytotoxicity receptors, NKp30 and NKp44, which synergized with the T-cell receptor to mediate leukemia cell targeting in vitro When transferred in vivo, DOT cells infiltrated tumors and peripheral organs, and persisted until the end of the analysis without showing signs of loss of function; indeed, DOT cells proliferated and produced abundant IFNγ and TNFα, but importantly no IL17, in vivo Critically, DOT cells were capable of inhibiting tumor growth and preventing dissemination in xenograft models of CLL.We provide a clinical-grade method and the preclinical proof of principle for application of a new cellular product, DOT cells, in adoptive immunotherapy of CLL. Clin Cancer Res; 22(23); 5795-804. ©2016 AACR.
PCM-13THE HYPOXIA-ACTIVATED PRODRUG EVOFOSFAMIDE (TH-302) IS EFFICACIOUS IN PEDIATRIC HIGH GRADE GLIOMA CELL LINES AS A MONOTHERAPY AND IN COMBINATION WITH CHEMOTHERAPIES
Authors: Pierre Leblond, Pauline Navarin, Mélanie Arcicasa, Christine Bal-Mahieu, Nicole Lemahieu, Pamela Völkel, Eric Lartigau, Pierre-Olivier Angrand, Samuel Meignan
Journal: Neuro-Oncology (2016)